M. Gibson, P. Savvides, F. Worden, R. Gopalakrishnan, T. Wu, R. Roden, E. Heimann-Nichols, Y.N. Chang
{"title":"评估使用 pBI-11 (IM) 和 TA-HPV (IM) 加上 Pembrolizumab 进行异源原代增殖治疗晚期、PD-L1 CPS≥1 和 hrHPV+ 口咽癌的安全性、有效性和免疫相关性的 II 期试验","authors":"M. Gibson, P. Savvides, F. Worden, R. Gopalakrishnan, T. Wu, R. Roden, E. Heimann-Nichols, Y.N. Chang","doi":"10.1016/j.ijrobp.2024.01.197","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":14219,"journal":{"name":"International Journal of Radiation Oncology*Biology*Physics","volume":"83 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Phase II Trial Assessing Safety, Efficacy and Immune Correlates of Heterologous Prime-Boost with pBI-11 (IM) and TA-HPV (IM) Plus Pembrolizumab for Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer\",\"authors\":\"M. Gibson, P. Savvides, F. Worden, R. Gopalakrishnan, T. Wu, R. Roden, E. Heimann-Nichols, Y.N. Chang\",\"doi\":\"10.1016/j.ijrobp.2024.01.197\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":14219,\"journal\":{\"name\":\"International Journal of Radiation Oncology*Biology*Physics\",\"volume\":\"83 4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Radiation Oncology*Biology*Physics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijrobp.2024.01.197\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology*Biology*Physics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2024.01.197","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Phase II Trial Assessing Safety, Efficacy and Immune Correlates of Heterologous Prime-Boost with pBI-11 (IM) and TA-HPV (IM) Plus Pembrolizumab for Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer